Monopar Therapeutics (MNPR) Common Equity (2016 - 2020)
Historic Common Equity for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $17.5 million.
- Monopar Therapeutics' Common Equity rose 27820.07% to $17.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.5 million, marking a year-over-year increase of 27820.07%. This contributed to the annual value of $12.6 million for FY2019, which is 8252.56% up from last year.
- Monopar Therapeutics' Common Equity amounted to $17.5 million in Q3 2020, which was up 27820.07% from $12.2 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Common Equity registered a high of $17.5 million during Q3 2020, and its lowest value of $2.8 million during Q4 2016.
- Its 5-year average for Common Equity is $8.8 million, with a median of $8.1 million in 2018.
- Per our database at Business Quant, Monopar Therapeutics' Common Equity plummeted by 3895.16% in 2019 and then surged by 27820.07% in 2020.
- Monopar Therapeutics' Common Equity (Quarter) stood at $2.8 million in 2016, then surged by 239.78% to $9.6 million in 2017, then decreased by 28.08% to $6.9 million in 2018, then skyrocketed by 82.53% to $12.6 million in 2019, then surged by 38.52% to $17.5 million in 2020.
- Its last three reported values are $17.5 million in Q3 2020, $12.2 million for Q2 2020, and $12.4 million during Q1 2020.